<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03736369</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWP14012301</org_study_id>
    <nct_id>NCT03736369</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Active-controlled, Parallel-Group, Phase 3, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of study is to confirm the efficacy of DWP14012 Xmg, Once daily, compared to
      esomeprazole 40mg in patients with erosive gastroesophageal reflux disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 13, 2018</start_date>
  <completion_date type="Actual">August 7, 2019</completion_date>
  <primary_completion_date type="Actual">August 7, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative healing rate of erosive esophagitis at 8week by endoscopy</measure>
    <time_frame>at 8week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative healing rate of erosive esophagitis at 4week by endoscopy</measure>
    <time_frame>at 4week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reflux disease symptom assessment using RDQ(Reflux disease questionnaire)</measure>
    <time_frame>at 4week and 8week</time_frame>
    <description>Mean change of the frequency or severity of main symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessment using GERD-HRQL(GERD-Health related quality life)</measure>
    <time_frame>at 4week and 8week</time_frame>
    <description>Mean change of the total score of GERD-HRQL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">263</enrollment>
  <condition>Erosive Esophagitis</condition>
  <arm_group>
    <arm_group_label>DWP14012 Xmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esomeprazole 40mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Orally, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012 Xmg</intervention_name>
    <description>DWP14012 X mg, tablet, orally, once daily for up to 8 weeks</description>
    <arm_group_label>DWP14012 Xmg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012 Xmg placebo</intervention_name>
    <description>DWP14012 Xmg placebo-matching tablet, orally, once daily for up to 8 weeks</description>
    <arm_group_label>Esomeprazole 40mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole 40mg</intervention_name>
    <description>Esomeprazole 40mg tablet, orally, once daily for up to 8 weeks</description>
    <arm_group_label>Esomeprazole 40mg</arm_group_label>
    <other_name>Nexium 40mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole 40mg placebo</intervention_name>
    <description>Esomeprazole 40mg placebo-matching tablet, orally, once daily for up to 8 weeks</description>
    <arm_group_label>DWP14012 Xmg</arm_group_label>
    <other_name>Nexium 40mg placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults between 20 and 75 years old based on the date of written agreement

          -  Those who have been diagnosed with erosive gastroesophageal reflux disease(EGRD) of LA
             Grade A-D on the upper gastrointestinal endoscopy

          -  Those who experienced symptoms of heartburn or acid regurgitation within the last 7
             days

        Exclusion Criteria:

          -  Those who have undergone gastric acid suppression or gastric, esophageal surgery

          -  Those who with clinically significant liver, kidney, nervous system, respiratory,
             endocrine, hematologic, cardiovascular, urinary system disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hanyang University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 26, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

